-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, UdH23o0WZuEXddHEDpD6J4wP9XTcMElFLFBIHHy67ckl0BpECHlijg5sBavgJ6Zl ogduqWrhxWicArM2dN+VQA== 0001128700-03-000014.txt : 20031112 0001128700-03-000014.hdr.sgml : 20031111 20031112133059 ACCESSION NUMBER: 0001128700-03-000014 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20031112 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: TUTOGEN MEDICAL INC CENTRAL INDEX KEY: 0000816949 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-MEDICAL, DENTAL & HOSPITAL EQUIPMENT & SUPPLIES [5047] IRS NUMBER: 593100165 STATE OF INCORPORATION: FL FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-41686 FILM NUMBER: 03992661 BUSINESS ADDRESS: STREET 1: 1719 ROUTE 10 STE 314 STREET 2: STE 130 CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 973-359-84 MAIL ADDRESS: STREET 1: 10500 UNIVERSITY CTR DR STREET 2: STE 130 CITY: TAMPA STATE: FL ZIP: 33612 FORMER COMPANY: FORMER CONFORMED NAME: BIODYNAMICS INTERNATIONAL INC DATE OF NAME CHANGE: 19930611 FORMER COMPANY: FORMER CONFORMED NAME: AMERICAN BIODYNAMICS INC DATE OF NAME CHANGE: 19920703 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: CAPITAL PARTNERS II LTD LIQUIDATING TRUST CENTRAL INDEX KEY: 0001128700 STANDARD INDUSTRIAL CLASSIFICATION: FINANCE SERVICES [6199] IRS NUMBER: 756590369 STATE OF INCORPORATION: TX FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 5646 MILTON ST STREET 2: STE 900 CITY: DALLAS STATE: TX ZIP: 75206 BUSINESS PHONE: 2143789340 MAIL ADDRESS: STREET 1: 5646 MILTON ST STREET 2: STE 900 CITY: DALLAS STATE: TX ZIP: 75206 SC 13D/A 1 sch13da5.txt Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5) TUTOGEN MEDICAL, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 901 107 10 2 (CUSIP Number) Thomas W. Pauken, Liquidating Trustee Capital Partners II, Ltd. Liquidating Trust (successor to Renaissance Capital Partners II, Ltd.) 5646 Milton Street, Suite 900 Dallas, Texas 75206 (214) 378-9340 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) November 7, 2003 (Date of Event Which Requires Filing of This Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. [ ] NOTE: Schedules filed in paper format shall include a signed original and five copies of the Schedule, including all exhibits. See Section 240.13d-7(b) for other parties to whom copies are to be sent. CUSIP No. 901 107 10 2 ______________________________________________________________________________ (1) Names of reporting persons I.R.S. Identification Nos. of above persons (entities only) Capital Partners II, Ltd. Liquidating Trust 75-6590369 ______________________________________________________________________________ (2) Check the appropriate box if a member of a group [ ] ______________________________________________________________________________ (3) SEC use only ______________________________________________________________________________ (4) Source of funds OO ______________________________________________________________________________ (5) Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) [ ] ______________________________________________________________________________ (6) Citizenship or place of organization Texas ______________________________________________________________________________ Number of shares beneficially owned by each reporting person with: (7) Sole voting power 3,624,926 ______________________________________________________________________________ (8) Shared voting power 0 ______________________________________________________________________________ (9) Sole dispositive power 3,624,926 ______________________________________________________________________________ (10) Shared dispositive power 0 ______________________________________________________________________________ (11) Aggregate amount beneficially owned by each reporting person 3,624,926 ______________________________________________________________________________ (12) Check if the aggregate amount in Row (11) excludes certain shares [ ] ______________________________________________________________________________ (13) Percent of class represented by amount in Row (11) 23.17 % ______________________________________________________________________________ (14) Type of reporting person OO ______________________________________________________________________________ Item 1. Security and Issuer The Schedule 13D filed by Renaissance Capital Partners II, Ltd. on February 10, 1999 with respect to securities of Tutogen Medical, Inc., as previously amended, is hereby further amended as set forth in this Amendment No. 5. Except as amended herein, the disclosure contained in the original Schedule 13D, as amended, remains in effect. Capitalized terms used but not defined herein shall have the meanings ascribed in the original Schedule 13D. Item 3. Source and Amount of Funds or Other Consideration This Amendment No. 5 does not report the acquisition of any additional securities. Item 4. Purpose of Transaction The proceeds of the sale identified in Item 5 below were used to reduce short term of indebtedness of the Trust and provide working capital for the Trust. On November 3, 2003, Tutogen issued a press release announcing that it has entered into a non-binding letter agreement with an unaffiliated private equity firm proposing to acquire all of the outstanding shares of common stock of Tutogen for $6.00 per share in cash. The proposal is subject to a due diligence review and the execution of definitive transaction documents. The text of the press release is filed as Exhibit 99.1 to a report on Form 8-K filed by Tutogen on November 4, 2003 and is incorporated herein by reference. Item 5. Interest in Securities of the Issuer On November 7, 2003, the Trustee sold 30,000 shares of Tutogen common stock for a price of $5.51 per share in a transaction on the American Stock Exchange. Following the sale, the Trust owned 3,624,926 shares of Tutogen common stock. Item 7. Material to be Filed as Exhibits None. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: November 11, 2003 CAPITAL PARTNERS II, LTD. LIQUIDATING TRUST By: _________/s/____________ Thomas W. Pauken Liquidating Trustee -----END PRIVACY-ENHANCED MESSAGE-----